Surged spending in healthcare infrastructure across developed as well as emerging economies are likely to keep the market agile in the coming years. Aimed at diminishing operational expenditure, several biopharmaceutical companies are entering into contractual agreements to outsource activities, thereby posing significant growth upswing in medical device contract manufacturing market.